| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution
|
Hosing, C.
|
|
|
26 |
12 |
p. 2490-2495
|
artikel
|
| 2 |
Alopecia in patients treated with molecularly targeted anticancer therapies
|
Belum, V.R.
|
|
|
26 |
12 |
p. 2496-2502
|
artikel
|
| 3 |
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
|
Nowak, A.K.
|
|
|
26 |
12 |
p. 2483-2490
|
artikel
|
| 4 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer
|
O'Neil, B.H.
|
|
|
26 |
12 |
p. 2505
|
artikel
|
| 5 |
A randomised trial of secondary prophylaxis using granulocyte colony-stimulating factor (‘SPROG’ trial) for maintaining dose intensity of standard adjuvant chemotherapy for breast cancer by the Anglo-Celtic Cooperative Group and NCRN
|
Leonard, R.C.F.
|
|
|
26 |
12 |
p. 2437-2441
|
artikel
|
| 6 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors
|
Nieto, Y.
|
|
|
26 |
12 |
p. 2507-2508
|
artikel
|
| 7 |
Breastfeeding and breast cancer risk by receptor status—a systematic review and meta-analysis
|
Islami, F.
|
|
|
26 |
12 |
p. 2398-2407
|
artikel
|
| 8 |
Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer
|
Takeda, M.
|
|
|
26 |
12 |
p. 2477-2482
|
artikel
|
| 9 |
Comment on ESMO Magnitude of Clinical Benefit Scale
|
Muhonen, T.
|
|
|
26 |
12 |
p. 2504
|
artikel
|
| 10 |
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature
|
Marous, M.
|
|
|
26 |
12 |
p. 2419-2428
|
artikel
|
| 11 |
Editorial board
|
|
|
|
26 |
12 |
p. ii-iii
|
artikel
|
| 12 |
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project †
|
Kramar, A.
|
|
|
26 |
12 |
p. 2392-2398
|
artikel
|
| 13 |
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
|
Gourgou-Bourgade, S.
|
|
|
26 |
12 |
p. 2505-2506
|
artikel
|
| 14 |
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial
|
Bianchini, G.
|
|
|
26 |
12 |
p. 2429-2436
|
artikel
|
| 15 |
Immunity and HER2-positive disease: never stop questioning
|
Loi, S.
|
|
|
26 |
12 |
p. 2361-2362
|
artikel
|
| 16 |
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer
|
Michels, J.
|
|
|
26 |
12 |
p. 2470-2477
|
artikel
|
| 17 |
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
|
Munzone, E.
|
|
|
26 |
12 |
p. 2442-2449
|
artikel
|
| 18 |
Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies
|
Lambertini, M.
|
|
|
26 |
12 |
p. 2408-2419
|
artikel
|
| 19 |
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer
|
Schirripa, M.
|
|
|
26 |
12 |
p. 2503
|
artikel
|
| 20 |
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
|
Kang, Y.-K.
|
|
|
26 |
12 |
p. 2457-2463
|
artikel
|
| 21 |
Statistical controversies in clinical research: long-term follow-up of clinical trials in cancer
|
Cuzick, J.
|
|
|
26 |
12 |
p. 2363-2366
|
artikel
|
| 22 |
Table of Contents
|
|
|
|
26 |
12 |
p. iv-v
|
artikel
|
| 23 |
Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era
|
Martin, S.D.
|
|
|
26 |
12 |
p. 2367-2374
|
artikel
|
| 24 |
The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer
|
Middleton, G.
|
|
|
26 |
12 |
p. 2464-2469
|
artikel
|
| 25 |
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
|
Naidoo, J.
|
|
|
26 |
12 |
p. 2375-2391
|
artikel
|
| 26 |
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
|
Sunakawa, Y.
|
|
|
26 |
12 |
p. 2450-2456
|
artikel
|
Tijdschrift beschrijving